A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

doi:10.1056/NEJMoa041588

Volume 351:2817-2826		December 30, 2004		Number 27

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

Soonmyung Paik, M.D., Steven Shak, M.D., Gong Tang, Ph.D., Chungyeul Kim, M.D., Joffre Baker, Ph.D., Maureen Cronin, Ph.D., Frederick L. Baehner, M.D., Michael G. Walker, Ph.D., Drew Watson, Ph.D., Taesung Park, Ph.D., William Hiller, H.T., Edwin R. Fisher, M.D., D. Lawrence Wickerham, M.D., John Bryant, Ph.D., and Norman Wolmark, M.D.

Full Text

PDF

PDA Full Text

PowerPoint Slide Set

Supplementary Material

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

PubMed Citation

ABSTRACT

Background The likelihood of distant recurrence in patientswith breast cancer who have no involved lymph nodes and estrogen-receptor–positivetumors is poorly defined by clinical and histopathological measures.

Methods We tested whether the results of a reverse-transcriptase–polymerase-chain-reaction(RT-PCR) assay of 21 prospectively selected genes in paraffin-embeddedtumor tissue would correlate with the likelihood of distantrecurrence in patients with node-negative, tamoxifen-treatedbreast cancer who were enrolled in the National Surgical AdjuvantBreast and Bowel Project clinical trial B-14. The levels ofexpression of 16 cancer-related genes and 5 reference geneswere used in a prospectively defined algorithm to calculatea recurrence score and to determine a risk group (low, intermediate,or high) for each patient.

Results Adequate RT-PCR profiles were obtained in 668 of 675tumor blocks. The proportions of patients categorized as havinga low, intermediate, or high risk by the RT-PCR assay were 51,22, and 27 percent, respectively. The Kaplan–Meier estimatesof the rates of distant recurrence at 10 years in the low-risk,intermediate-risk, and high-risk groups were 6.8 percent (95percent confidence interval, 4.0 to 9.6), 14.3 percent (95 percentconfidence interval, 8.3 to 20.3), and 30.5 percent (95 percentconfidence interval, 23.6 to 37.4). The rate in the low-riskgroup was significantly lower than that in the high-risk group(P<0.001). In a multivariate Cox model, the recurrence scoreprovided significant predictive power that was independent ofage and tumor size (P<0.001). The recurrence score was alsopredictive of overall survival (P<0.001) and could be usedas a continuous function to predict distant recurrence in individualpatients.

Conclusions The recurrence score has been validated as quantifyingthe likelihood of distant recurrence in tamoxifen-treated patientswith node-negative, estrogen-receptor–positive breastcancer.

Source Information

From the Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh (S.P., G.T., C.K., T.P., W.H., E.R.F., D.L.W., J.B., N.W.); Genomic Health, Redwood City, Calif. (S.S., J.B., M.C., M.G.W., D.W.); the Department of Statistics, University of Pittsburgh, Pittsburgh (G.T., J.B.); and the University of California, San Francisco, San Francisco (F.L.B.).

Address reprint requests to Dr. Paik at the Division of Pathology, NSABP, 4 Allegheny Center, 5th Fl., East Commons Professional Bldg., Pittsburgh, PA 15212, or at spaik.nejm{at}nsabp.org.

Full Text of this Article

This article has been cited by other articles:

Helms, M. W., Kemming, D., Contag, C. H., Pospisil, H., Bartkowiak, K., Wang, A., Chang, S.-Y., Buerger, H., Brandt, B. H. (2009). TOB1 Is Regulated by EGF-Dependent HER2 and EGFR Signaling, Is Highly Phosphorylated, and Indicates Poor Prognosis in Node-Negative Breast Cancer. Cancer Res. 69: 5049-5056 [Abstract] [Full Text]
Yeatman, T. J. (2009). Predictive Biomarkers: Identification and Verification. JCO 27: 2743-2744 [Full Text]
Guinebretiere, J. M. (2009). Cancer Is Heterogeneous. JCO 27: 2732-2732 [Full Text]
Badve, S. S., Baehner, F. L., Gray, R. P., Childs, B. H., Maddala, T., Liu, M.-L., Rowley, S. C., Shak, S., Perez, E. A., Shulman, L. J., Martino, S., Davidson, N. E., Sledge, G. W., Goldstein, L. J., Sparano, J. A. (2009). Reply to J.M. Guinebretiere and L. Arnould et al. JCO 27: 2734-2735 [Full Text]
Onitilo, A. A., Engel, J. M., Greenlee, R. T., Mukesh, B. N. (2009). Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res 7: 4-13 [Abstract] [Full Text]
Cheang, M. C. U., Chia, S. K., Voduc, D., Gao, D., Leung, S., Snider, J., Watson, M., Davies, S., Bernard, P. S., Parker, J. S., Perou, C. M., Ellis, M. J., Nielsen, T. O. (2009). Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer. JNCI J Natl Cancer Inst 101: 736-750 [Abstract] [Full Text]
Gordon, G. J., Dong, L., Yeap, B. Y., Richards, W. G., Glickman, J. N., Edenfield, H., Mani, M., Colquitt, R., Maulik, G., Van Oss, B., Sugarbaker, D. J., Bueno, R. (2009). Four-Gene Expression Ratio Test for Survival in Patients Undergoing Surgery for Mesothelioma. JNCI J Natl Cancer Inst 101: 678-686 [Abstract] [Full Text]
Mannefeld, M., Klassen, E., Gaubatz, S. (2009). B-MYB Is Required for Recovery from the DNA Damage-Induced G2 Checkpoint in p53 Mutant Cells. Cancer Res. 69: 4073-4080 [Abstract] [Full Text]
Wang, R., Morris, D. S., Tomlins, S. A., Lonigro, R. J., Tsodikov, A., Mehra, R., Giordano, T. J., Kunju, L. P., Lee, C. T., Weizer, A. Z., Chinnaiyan, A. M. (2009). Development of a Multiplex Quantitative PCR Signature to Predict Progression in Non-Muscle-Invasive Bladder Cancer. Cancer Res. 69: 3810-3818 [Abstract] [Full Text]
DE CREMOUX, P., GRANDIN, L., DIERAS, V., SAVIGNONI, A., DEGEORGES, A., SALMON, R., BOLLET, M. A., REYAL, F., SIGAL-ZAFRANI, B., VINCENT-SALOMON, A., SASTRE-GARAU, X., MAGDELENAT, H., MIGNOT, L., FOURQUET, A., ON BEHALF OF THE BREAST CANCER STUDY GROUP OF THE, (2009). Urokinase-type Plasminogen Activator and Plasminogen-activator-inhibitor Type 1 Predict Metastases in Good Prognosis Breast Cancer Patients. Anticancer Res 29: 1475-1482 [Abstract] [Full Text]
Leek, J. T. (2009). The tspair package for finding top scoring pair classifiers in R. Bioinformatics 25: 1203-1204 [Abstract] [Full Text]
Borczuk, A. C., Toonkel, R. L., Powell, C. A. (2009). Genomics of Lung Cancer. Proc Am Thorac Soc 6: 152-158 [Abstract] [Full Text]
Cheng, C.-J., Lin, Y.-C., Tsai, M.-T., Chen, C.-S., Hsieh, M.-C., Chen, C.-L., Yang, R.-B. (2009). SCUBE2 Suppresses Breast Tumor Cell Proliferation and Confers a Favorable Prognosis in Invasive Breast Cancer. Cancer Res. 69: 3634-3641 [Abstract] [Full Text]
Kashani-Sabet, M., Rangel, J., Torabian, S., Nosrati, M., Simko, J., Jablons, D. M., Moore, D. H., Haqq, C., Miller, J. R. III, Sagebiel, R. W. (2009). A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc. Natl. Acad. Sci. USA 106: 6268-6272 [Abstract] [Full Text]
Merlo, A., Casalini, P., Carcangiu, M. L., Malventano, C., Triulzi, T., Menard, S., Tagliabue, E., Balsari, A. (2009). FOXP3 Expression and Overall Survival in Breast Cancer. JCO 27: 1746-1752 [Abstract] [Full Text]
Pitroda, S. P., Khodarev, N. N., Beckett, M. A., Kufe, D. W., Weichselbaum, R. R. (2009). From the Cover: MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc. Natl. Acad. Sci. USA 106: 5837-5841 [Abstract] [Full Text]
Mustacchi, G., Mansutti, M., Sacco, C., Barni, S., Farris, A., Cazzaniga, M., Cozzi, M., Dellach, C. (2009). Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study. Ann Oncol 20: 655-659 [Abstract] [Full Text]
Overdevest, J. B., Theodorescu, D., Lee, J. K. (2009). Utilizing the Molecular Gateway: The Path to Personalized Cancer Management. Clin. Chem. 55: 684-697 [Abstract] [Full Text]
Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., Hortobagyi, G. N. (2009). The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. The Oncologist 14: 320-368 [Abstract] [Full Text]
Roukos, D. H. (2009). Twenty-One-Gene Assay: Challenges and Promises in Translating Personal Genomics and Whole-Genome Scans Into Personalized Treatment of Breast Cancer. JCO 27: 1337-1338 [Full Text]
Hugh, J., Hanson, J., Cheang, M. C. U., Nielsen, T. O., Perou, C. M., Dumontet, C., Reed, J., Krajewska, M., Treilleux, I., Rupin, M., Magherini, E., Mackey, J., Martin, M., Vogel, C. (2009). Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial. JCO 27: 1168-1176 [Abstract] [Full Text]
Parker, J. S., Mullins, M., Cheang, M. C.U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., Quackenbush, J. F., Stijleman, I. J., Palazzo, J., Marron, J.S., Nobel, A. B., Mardis, E., Nielsen, T. O., Ellis, M. J., Perou, C. M., Bernard, P. S. (2009). Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. JCO 27: 1160-1167 [Abstract] [Full Text]
Sorlie, T. (2009). Introducing Molecular Subtyping of Breast Cancer Into the Clinic?. JCO 27: 1153-1154 [Full Text]
de Reynies, A., Assie, G., Rickman, D. S., Tissier, F., Groussin, L., Rene-Corail, F., Dousset, B., Bertagna, X., Clauser, E., Bertherat, J. (2009). Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival. JCO 27: 1108-1115 [Abstract] [Full Text]
Ma, W. W., Adjei, A. A. (2009). Novel Agents on the Horizon for Cancer Therapy. CA Cancer J Clin 59: 111-137 [Abstract] [Full Text]
Brewer, N. T., Tzeng, J. P., Lillie, S. E., Edwards, A. S., Peppercorn, J. M., Rimer, B. K. (2009). Health Literacy and Cancer Risk Perception: Implications for Genomic Risk Communication. Med Decis Making 29: 157-166 [Abstract]
Jeruss, J. S., Woodruff, T. K. (2009). Preservation of Fertility in Patients with Cancer. NEJM 360: 902-911 [Full Text]
Sotiriou, C., Pusztai, L. (2009). Gene-Expression Signatures in Breast Cancer. NEJM 360: 790-800 [Full Text]
Waldman, S. A., Hyslop, T., Schulz, S., Barkun, A., Nielsen, K., Haaf, J., Bonaccorso, C., Li, Y., Weinberg, D. S. (2009). Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer. JAMA 301: 745-752 [Abstract] [Full Text]
Choi, Y. H., Ahn, J. H., Kim, S.-B., Jung, K.-H., Gong, G.-Y., Kim, M.-J., Son, B.-H., Ahn, S.-H., Kim, W. K. (2009). Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol 0: mdp003v1-mdp003 [Abstract] [Full Text]
Ghayad, S. E, Vendrell, J. A, Bieche, I., Spyratos, F., Dumontet, C., Treilleux, I., Lidereau, R., Cohen, P. A (2009). Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol 42: 87-103 [Abstract] [Full Text]
van Agthoven, T., Sieuwerts, A. M., Meijer-van Gelder, M. E., Look, M. P., Smid, M., Veldscholte, J., Sleijfer, S., Foekens, J. A., Dorssers, L. C.J. (2009). Relevance of Breast Cancer Antiestrogen Resistance Genes in Human Breast Cancer Progression and Tamoxifen Resistance. JCO 27: 542-549 [Abstract] [Full Text]
Mandelblatt, J. S., Silliman, R. (2009). Hanging in the Balance: Making Decisions About the Benefits and Harms of Breast Cancer Screening Among the Oldest Old Without a Safety Net of Scientific Evidence. JCO 27: 487-490 [Full Text]
Bergh, J. (2009). Quo Vadis With Targeted Drugs in the 21st Century?. JCO 27: 2-5 [Full Text]
Lukes, L., Crawford, N. P.S., Walker, R., Hunter, K. W. (2009). The Origins of Breast Cancer Prognostic Gene Expression Profiles. Cancer Res. 69: 310-318 [Abstract] [Full Text]
Badve, S, Nakshatri, H (2009). Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J. Clin. Pathol. 62: 6-12 [Abstract] [Full Text]
Morris, P. G., McArthur, H. L., Dang, C. T., Hudis, C. A. (2009). Selection of Appropriate Patients for Anthracycline Therapy. Am Soc Clin Oncol Ed Book 2009: 11-18 [Abstract] [Full Text]
Olopade, O. I., Grushko, T. A., Nanda, R., Huo, D. (2008). Advances in Breast Cancer: Pathways to Personalized Medicine. Clin. Cancer Res. 14: 7988-7999 [Abstract] [Full Text]
Dowsett, M., Dunbier, A. K. (2008). Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer. Clin. Cancer Res. 14: 8019-8026 [Abstract] [Full Text]
Guo, N. L., Wan, Y.-W., Tosun, K., Lin, H., Msiska, Z., Flynn, D. C., Remick, S. C., Vallyathan, V., Dowlati, A., Shi, X., Castranova, V., Beer, D. G., Qian, Y. (2008). Confirmation of Gene Expression-Based Prediction of Survival in Non-Small Cell Lung Cancer. Clin. Cancer Res. 14: 8213-8220 [Abstract] [Full Text]
Hassett, M. J., Hughes, M. E., Niland, J. C., Edge, S. B., Theriault, R. L., Wong, Y.-N., Wilson, J., Carter, W. B., Blayney, D. W., Weeks, J. C. (2008). Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer. JCO 26: 5553-5560 [Abstract] [Full Text]
de Vries, E. G.E., de Jong, S. (2008). Exploiting the Apoptotic Route for Cancer Treatment: A Single Hit Will Rarely Result in a Home Run. JCO 26: 5151-5153 [Full Text]
Harbeck, N., Nimmrich, I., Hartmann, A., Ross, J. S., Cufer, T., Grutzmann, R., Kristiansen, G., Paradiso, A., Hartmann, O., Margossian, A., Martens, J., Schwope, I., Lukas, A., Muller, V., Milde-Langosch, K., Nahrig, J., Foekens, J., Maier, S., Schmitt, M., Lesche, R. (2008). Multicenter Study Using Paraffin-Embedded Tumor Tissue Testing PITX2 DNA Methylation As a Marker for Outcome Prediction in Tamoxifen-Treated, Node-Negative Breast Cancer Patients. JCO 26: 5036-5042 [Abstract] [Full Text]
Somlo, G., Chu, P., Frankel, P., Ye, W., Groshen, S., Doroshow, J. H., Danenberg, K., Danenberg, P. (2008). Molecular profiling including epidermal growth factor receptor and p21 expression in high-risk breast cancer patients as indicators of outcome. Ann Oncol 19: 1853-1859 [Abstract] [Full Text]
Allred, D. C. (2008). Commentary: Hormone Receptor Testing in Breast Cancer: A Distress Signal from Canada. The Oncologist 13: 1134-1136 [Full Text]
Ransohoff, D. F. (2008). The Process to Discover and Develop Biomarkers for Cancer: A Work in Progress. JNCI J Natl Cancer Inst 100: 1419-1420 [Full Text]
Ross, D. T., Kim, C.-y., Tang, G., Bohn, O. L., Beck, R. A., Ring, B. Z., Seitz, R. S., Paik, S., Costantino, J. P., Wolmark, N. (2008). Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials. Clin. Cancer Res. 14: 6602-6609 [Abstract] [Full Text]
Webster, L. R., Lee, S.-F., Ringland, C., Morey, A. L., Hanby, A. M., Morgan, G., Byth, K., Mote, P. A., Provan, P. J., Ellis, I. O., Green, A. R., Lamoury, G., Ravdin, P., Clarke, C. L., Ward, R. L., Balleine, R. L., Hawkins, N. J. (2008). Poor-Prognosis Estrogen Receptor-Positive Breast Cancer Identified by Histopathologic Subclassification. Clin. Cancer Res. 14: 6625-6633 [Abstract] [Full Text]
Pusztai, L., Broglio, K., Andre, F., Symmans, W. F., Hess, K. R., Hortobagyi, G. N. (2008). Effect of Molecular Disease Subsets on Disease-Free Survival in Randomized Adjuvant Chemotherapy Trials for Estrogen Receptor-Positive Breast Cancer. JCO 26: 4679-4683 [Abstract] [Full Text]
Conzen, S. D. (2008). Minireview: Nuclear Receptors and Breast Cancer. Mol. Endocrinol. 22: 2215-2228 [Abstract] [Full Text]
Ellis, M. J., Tao, Y., Luo, J., A'Hern, R., Evans, D. B., Bhatnagar, A. S., Chaudri Ross, H. A., von Kameke, A., Miller, W. R., Smith, I., Eiermann, W., Dowsett, M. (2008). Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics. JNCI J Natl Cancer Inst 100: 1380-1388 [Abstract] [Full Text]
Taylor, J. M.G., Ankerst, D. P., Andridge, R. R. (2008). Validation of Biomarker-Based Risk Prediction Models. Clin. Cancer Res. 14: 5977-5983 [Abstract] [Full Text]
Simon, R. (2008). The Use of Genomics in Clinical Trial Design. Clin. Cancer Res. 14: 5984-5993 [Abstract] [Full Text]
Yeatman, T. J., Mule, J., Dalton, W. S., Sullivan, D. (2008). On the Eve of Personalized Medicine in Oncology. Cancer Res. 68: 7250-7252 [Full Text]
Srivastava, S., Gray, J. W., Reid, B. J., Grad, O., Greenwood, A., Hawk, E. T., for the Translational Research Working Group, (2008). Translational Research Working Group Developmental Pathway for Biospecimen-Based Assessment Modalities. Clin. Cancer Res. 14: 5672-5677 [Abstract] [Full Text]
Goetz, M. P., Suman, V. J., Couch, F. J., Ames, M. M., Rae, J. M., Erlander, M. G., Ma, X.-J., Sgroi, D. C., Reynolds, C. A., Lingle, W. L., Weinshilboum, R. M., Flockhart, D. A., Desta, Z., Perez, E. A., Ingle, J. N. (2008). Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance. Clin. Cancer Res. 14: 5864-5868 [Abstract] [Full Text]
Rutgers, E. J.T., Pusztai, L., Bernards, R. (2008). Are Short-Term or Long-Term Recurrence Rates More Important in Breast Cancer Screening?. ANN INTERN MED 149: 357-357 [Full Text]
Goldstein, L. J., Gray, R., Badve, S., Childs, B. H., Yoshizawa, C., Rowley, S., Shak, S., Baehner, F. L., Ravdin, P. M., Davidson, N. E., Sledge, G. W. Jr, Perez, E. A., Shulman, L. N., Martino, S., Sparano, J. A. (2008). Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. JCO 26: 4063-4071 [Abstract] [Full Text]
Paik, S., Tang, G., Fumagalli, D. (2008). An Ideal Prognostic Test for Estrogen Receptor-Positive Breast Cancer?. JCO 26: 4058-4059 [Full Text]
Jeruss, J. S., Mittendorf, E. A., Tucker, S. L., Gonzalez-Angulo, A. M., Buchholz, T. A., Sahin, A. A., Cormier, J. N., Buzdar, A. U., Hortobagyi, G. N., Hunt, K. K. (2008). Staging of Breast Cancer in the Neoadjuvant Setting. Cancer Res. 68: 6477-6481 [Abstract] [Full Text]
Desmedt, C., Haibe-Kains, B., Wirapati, P., Buyse, M., Larsimont, D., Bontempi, G., Delorenzi, M., Piccart, M., Sotiriou, C. (2008). Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes. Clin. Cancer Res. 14: 5158-5165 [Abstract] [Full Text]
John, T., Black, M. A., Toro, T. T., Leader, D., Gedye, C. A., Davis, I. D., Guilford, P. J., Cebon, J. S. (2008). Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma. Clin. Cancer Res. 14: 5173-5180 [Abstract] [Full Text]
Hershman, D. L., Neugut, A. I. (2008). Anthracycline Cardiotoxicity: One Size Does Not Fit All!. JNCI J Natl Cancer Inst 100: 1046-1047 [Full Text]
Fung, E. T, Wilson, A. M, Zhang, F., Harris, N., Edwards, K. A, Olin, J. W, Cooke, J. P (2008). A biomarker panel for peripheral arterial disease. Vasc Med 13: 217-224 [Abstract]
Skrzypski, M., Jassem, E., Taron, M., Sanchez, J. J., Mendez, P., Rzyman, W., Gulida, G., Raz, D., Jablons, D., Provencio, M., Massuti, B., Chaib, I., Perez-Roca, L., Jassem, J., Rosell, R. (2008). Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. Clin. Cancer Res. 14: 4794-4799 [Abstract] [Full Text]
Turner, N. C, Jones, A. L (2008). Management of breast cancer--Part II. BMJ 337: a540-a540 [Full Text]
Peppercorn, J., Partridge, A. H. (2008). Breast Cancer in Young Women: A New Color or a Different Shade of Pink?. JCO 26: 3303-3305 [Full Text]
Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., Wang, Y., Marcom, P. K., Marks, J. R., Febbo, P. G., Nevins, J. R., Potti, A., Blackwell, K. L. (2008). Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression. JCO 26: 3324-3330 [Abstract] [Full Text]
Sierra, J. R., Corso, S., Caione, L., Cepero, V., Conrotto, P., Cignetti, A., Piacibello, W., Kumanogoh, A., Kikutani, H., Comoglio, P. M., Tamagnone, L., Giordano, S. (2008). Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. JEM 205: 1673-1685 [Abstract] [Full Text]
Colman, H., Aldape, K. (2008). Molecular Predictors in Glioblastoma: Toward Personalized Therapy. Arch Neurol 65: 877-883 [Abstract] [Full Text]
Lee, C. W., Raskett, C. M., Prudovsky, I., Altieri, D. C. (2008). Molecular Dependence of Estrogen Receptor-Negative Breast Cancer on a Notch-Survivin Signaling Axis. Cancer Res. 68: 5273-5281 [Abstract] [Full Text]
Schmidt, M., Bohm, D., von Torne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H.-A., Hengstler, J. G., Kolbl, H., Gehrmann, M. (2008). The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer. Cancer Res. 68: 5405-5413 [Abstract] [Full Text]
Grube, B. J., Christy, C. J., Black, D., Martel, M., Harris, L., Weidhaas, J., DiGiovanna, M. P., Chung, G., Abu-Khalaf, M. M., Miller, K. D., Higgins, S. A., Philpotts, L., Tavassoli, F. A., Lannin, D. R. (2008). Breast Sentinel Lymph Node Dissection Before Preoperative Chemotherapy. Arch Surg 143: 692-700 [Abstract] [Full Text]
Regan, M. M., Pagani, O., Walley, B., Torrisi, R., Perez, E. A., Francis, P., Fleming, G. F., Price, K. N., Thurlimann, B., Maibach, R., Castiglione-Gertsch, M., Coates, A. S., Goldhirsch, A., Gelber, R. D., for the SOFT/TEXT/PERCHE Steering Committee and th, (2008). Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol 19: 1231-1241 [Abstract] [Full Text]
Cappelletti, V., Gariboldi, M., De Cecco, L., Toffanin, S., Reid, J. F, Lusa, L., Bajetta, E., Celio, L., Greco, M., Fabbri, A., Pierotti, M. A, Daidone, M. G. (2008). Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer. Endocr Relat Cancer 15: 439-449 [Abstract] [Full Text]
Andre, F., Broglio, K., Roche, H., Martin, M., Mackey, J. R., Penault-Llorca, F., Hortobagyi, G. N., Pusztai, L. (2008). Estrogen Receptor Expression and Efficacy of Docetaxel-Containing Adjuvant Chemotherapy in Patients With Node-Positive Breast Cancer: Results From a Pooled Analysis. JCO 26: 2636-2643 [Abstract] [Full Text]
Sauer, G., Schneiderhan-Marra, N., Kazmaier, C., Hutzel, K., Koretz, K., Muche, R., Kreienberg, R., Joos, T., Deissler, H. (2008). Prediction of Nodal Involvement in Breast Cancer Based on Multiparametric Protein Analyses from Preoperative Core Needle Biopsies of the Primary Lesion. Clin. Cancer Res. 14: 3345-3353 [Abstract] [Full Text]
Allred, D. C. (2008). Problems and Solutions in the Evaluation of Hormone Receptors in Breast Cancer. JCO 26: 2433-2435 [Full Text]
Badve, S. S., Baehner, F. L., Gray, R. P., Childs, B. H., Maddala, T., Liu, M.-L., Rowley, S. C., Shak, S., Perez, E. D., Shulman, L. J., Martino, S., Davidson, N. E., Sledge, G. W., Goldstein, L. J., Sparano, J. A. (2008). Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. JCO 26: 2473-2481 [Abstract] [Full Text]
Ma, X.-J., Salunga, R., Dahiya, S., Wang, W., Carney, E., Durbecq, V., Harris, A., Goss, P., Sotiriou, C., Erlander, M., Sgroi, D. (2008). A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clin. Cancer Res. 14: 2601-2608 [Abstract] [Full Text]
Brennan, D. J., Rexhepaj, E., O'Brien, S. L., McSherry, E., O'Connor, D. P., Fagan, A., Culhane, A. C., Higgins, D. G., Jirstrom, K., Millikan, R. C., Landberg, G., Duffy, M. J., Hewitt, S. M., Gallagher, W. M. (2008). Altered Cytoplasmic-to-Nuclear Ratio of Survivin Is a Prognostic Indicator in Breast Cancer. Clin. Cancer Res. 14: 2681-2689 [Abstract] [Full Text]
Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., Hortobagyi, G. N. (2008). Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer. The Oncologist 13: 477-493 [Abstract] [Full Text]
Cardoso, F., Saghatchian, M., Thompson, A., Rutgers, E., for the TRANSBIG Consortium Steering Committee, (2008). Inconsistent Criteria Used in American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. JCO 26: 2058-2059 [Full Text]
Harris, L. N., Hayes, D. F., Bast, R. C. (2008). In Reply. JCO 26: 2060-2061 [Full Text]
Lin, N. U., Winer, E. P. (2008). Optimizing Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: Treating the Right Patients for the Right Length of Time. JCO 26: 1919-1921 [Full Text]
Sgroi, D. (2008). Real-Time PCR Biomarker Analysis Using Routine Pathology Specimens. aacredbook 2008: 529-530 [Full Text]
Acharya, C. R., Hsu, D. S., Anders, C. K., Anguiano, A., Salter, K. H., Walters, K. S., Redman, R. C., Tuchman, S. A., Moylan, C. A., Mukherjee, S., Barry, W. T., Dressman, H. K., Ginsburg, G. S., Marcom, K. P., Garman, K. S., Lyman, G. H., Nevins, J. R., Potti, A. (2008). Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer. JAMA 299: 1574-1587 [Abstract] [Full Text]
Park, B.-W., Oh, J.-W., Kim, J.-H., Park, S. H., Kim, K.-S., Kim, J. H., Lee, K. S. (2008). Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 19: 675-681 [Abstract] [Full Text]
Pusztai, L. (2008). Current Status of Prognostic Profiling in Breast Cancer. The Oncologist 13: 350-360 [Abstract] [Full Text]
Chanrion, M., Negre, V., Fontaine, H., Salvetat, N., Bibeau, F., Grogan, G. M., Mauriac, L., Katsaros, D., Molina, F., Theillet, C., Darbon, J.-M. (2008). A Gene Expression Signature that Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer. Clin. Cancer Res. 14: 1744-1752 [Abstract] [Full Text]
Rudas, M., Lehnert, M., Huynh, A., Jakesz, R., Singer, C., Lax, S., Schippinger, W., Dietze, O., Greil, R., Stiglbauer, W., Kwasny, W., Grill, R., Stierer, M., Gnant, M. F.X., Filipits, M., for the Austrian Breast and Colorectal Cancer Stud, (2008). Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. Clin. Cancer Res. 14: 1767-1774 [Abstract] [Full Text]
Bear, H. D. (2008). Measuring Circulating Tumor Cells As a Surrogate End Point for Adjuvant Therapy of Breast Cancer: What Do They Mean and What Should We Do About Them?. JCO 26: 1195-1197 [Full Text]

Comments and questions? Please contact us.